Project Grant K99CA297120
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$122K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to conduct research on the role of CD91-mediated signaling in cancer immunosurveillance. The research aims to develop a new mouse model to test the importance of CD91 signaling in response to tumor-derived heat shock proteins (HSPs) for priming T cell responses against nascent, emerging tumors. The goal is to better understand the mechanisms by...
The National Cancer Institute (NCI) awarded a $149,804 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh. The award will fund research to investigate the impact of the LAG3 protein on CD8+ T cell motility and migration in the context of cancer immunotherapy. The project aims to elucidate the mechanism by which LAG3 restricts T cell motility and determine if reduced motility impacts T cell infiltration into the tumor microenvironment. The...
This Project Grant award of $147,486 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research at the University of Pittsburgh to investigate the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment. The project aims to (1) evaluate the impact of abolishing citrate transport on carbon utilization and effector function of CD8 T cells in the tumor environment, and (2) determine the role of stored lipids in CD8 T cell...
The University of Pittsburgh was awarded a $1,271,780 Project Grant by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), to develop small molecule adaptors for precision control of universal chimeric antigen receptor (CAR) T cell therapy. The project aims to: 1) create small molecule adaptors for targeting universal CARs to multiple antigens, including tumor cells and immunosuppressive cells; 2) enhance CAR targeting specificity using chemical...
This Project Grant award of $445,996 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate how mitigating oxidative stress at T cell telomeres can improve the function and efficacy of adoptive cell therapies against cancer. The research, conducted by the University of Pittsburgh, has two key objectives: Determine the mechanistic role of oxidative damage at telomeres on T cell function and how protecting telomeres with an antioxidant protein can...
The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the University of Pittsburgh. The project aims to investigate the functional consequences of high glucose culture on adoptive T cell therapies for cancer. Specifically, the research will (1) identify cellular proteins that are differentially O-GlcNAcylated under high glucose conditions and determine if inhibiting O-GlcNAcylation can restore T cell...
This Project Grant award of $673,526 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Pittsburgh to investigate the mechanistic role of p16 loss in regulating zinc homeostasis through the zinc transporter SLC39A9 and its impact on the efficacy of immune checkpoint blockade therapy in melanoma. The research aims to explore whether manipulating zinc levels can enhance the effectiveness of current immune...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania is focused on engineering a protein therapeutic to limit the transformation of the patient's own anti-tumor autoantibodies into highly potent T cell-redirecting antibodies, specifically within the tumor microenvironment. The $216,682 award, effective March 1, 2025 through February 28, 2027, aims to optimize the engineered protein therapeutic...
The National Cancer Institute (NCI) awarded a $585,931 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Pittsburgh. The grant, effective February 3, 2025 through January 31, 2030, will support a research project titled "Single-Cell Congruence Evaluation and Selection of Cancer Models Towards Precision Medicine." The project aims to: 1) Identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer,...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...